Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-8.19%
$37.62
0% positive prob.
5-Day Prediction
-11.10%
$36.43
0% positive prob.
20-Day Prediction
-13.12%
$35.61
0% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q4 2025 | SELL | -8.19% | -11.10% | -13.12% | 100.0% | Pending |
| Q3 2025 | SELL | -8.96% | -12.76% | -14.49% | 100.0% | -2.80% |
SEC 8-K filings with transcript text
Mar 11, 2026 · 100% conf.
1D
-8.19%
$37.62
Act: -1.06%
5D
-11.10%
$36.43
20D
-13.12%
$35.61
kequ-20260311KEWAUNEE SCIENTIFIC CORP /DE/FALSE000005552900000555292026-03-112026-03-11
Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2026
Kewaunee Scientific Corporation (Exact name of registrant as specified in its charter)
Delaware 0-5286 38-0715562 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)
2700 West Front Street Statesville, NC 28677 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (704) 873-7202 N/A (Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $2.50 par value KEQUThe Nasdaq Global Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On March 11, 2026, Kewaunee Scientific Corporation issued a press release announcing its financial results for the third quarter of fiscal year 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1Press Release of Kewaunee Scientific Corporation dated March 11, 2026.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: March 11, 2026 By/s/ Donald T. Gardner III Donald T. Gardner III Vice President, Finance Chief Financial Officer
Dec 10, 2025 · 100% conf.
1D
-8.96%
$36.42
Act: -4.35%
5D
-12.76%
$34.90
Act: -2.80%
20D
-14.49%
$34.20
Act: -6.25%
kequ-20251210KEWAUNEE SCIENTIFIC CORP /DE/FALSE000005552900000555292025-12-102025-12-10
Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2025
Kewaunee Scientific Corporation (Exact name of registrant as specified in its charter)
Delaware 0-5286 38-0715562 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)
2700 West Front Street Statesville, NC 28677 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (704) 873-7202 N/A (Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $2.50 par value KEQUThe Nasdaq Global Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On December 10, 2025, Kewaunee Scientific Corporation issued a press release announcing its financial results for the second quarter of fiscal year 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1Press Release of Kewaunee Scientific Corporation dated December 10, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: December 10, 2025 By/s/ Donald T. Gardner III Donald T. Gardner III Vice President, Finance Chief Financial Officer
Sep 10, 2025
kequ-20250910KEWAUNEE SCIENTIFIC CORP /DE/FALSE000005552900000555292025-09-102025-09-10
Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2025
Kewaunee Scientific Corporation (Exact name of registrant as specified in its charter)
Delaware 0-5286 38-0715562 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)
2700 West Front Street Statesville, NC 28677 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (704) 873-7202 N/A (Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $2.50 par value KEQUThe Nasdaq Global Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On September 10, 2025, Kewaunee Scientific Corporation issued a press release announcing its financial results for the first quarter of fiscal year 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1Press Release of Kewaunee Scientific Corporation dated September 10, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: September 10, 2025 By/s/ Donald T. Gardner III Donald T. Gardner III Vice President, Finance Chief Financial Officer
Jun 26, 2025
kequ-20250625FALSE000005552900000555292025-06-252025-06-25
Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025
Kewaunee Scientific Corporation (Exact name of registrant as specified in its charter)
Delaware 0-5286 38-0715562 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)
2700 West Front Street Statesville, NC 28677 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (704) 873-7202 N/A (Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $2.50 par value KEQUThe Nasdaq Global Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On June 25, 2025, Kewaunee Scientific Corporation issued a press release announcing financial results for its fourth quarter and its fiscal year ended April 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1Press Release of Kewaunee Scientific Corporation dated June 25, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: June 25, 2025 By/s/ Donald T. Gardner III Donald T. Gardner III Vice President, Finance Chief Financial Officer
Mar 12, 2025
kequ-20250312KEWAUNEE SCIENTIFIC CORP /DE/FALSE000005552900000555292025-03-122025-03-12
Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2025
Kewaunee Scientific Corporation (Exact name of registrant as specified in its charter)
Delaware 0-5286 38-0715562 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)
2700 West Front Street Statesville, NC 28677 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (704) 873-7202 N/A (Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $2.50 par value KEQUThe Nasdaq Global Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On March 12, 2025, Kewaunee Scientific Corporation issued a press release announcing its financial results for the third quarter of fiscal year 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1Press Release of Kewaunee Scientific Corporation dated March 12, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: March 12, 2025 By/s/ Donald T. Gardner III Donald T. Gardner III Vice President, Finance Chief Financial Officer
Dec 11, 2024
kequ-20241211KEWAUNEE SCIENTIFIC CORP /DE/FALSE000005552900000555292024-12-112024-12-11
Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2024
Kewaunee Scientific Corporation (Exact name of registrant as specified in its charter)
Delaware 0-5286 38-0715562 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)
2700 West Front Street Statesville, NC 28677 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (704) 873-7202 N/A (Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $2.50 par value KEQUThe Nasdaq Global Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On December 11, 2024, Kewaunee Scientific Corporation issued a press release announcing its financial results for the second quarter of fiscal year 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1Press Release of Kewaunee Scientific Corporation dated December 11, 2024.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: December 11, 2024 By/s/ Donald T. Gardner III Donald T. Gardner III Vice President, Finance Chief Financial Officer
Sep 11, 2024
kequ-20240911KEWAUNEE SCIENTIFIC CORP /DE/FALSE000005552900000555292024-09-112024-09-11
Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2024
Kewaunee Scientific Corporation (Exact name of registrant as specified in its charter)
Delaware 0-5286 38-0715562 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)
2700 West Front Street Statesville, NC 28677 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (704) 873-7202 N/A (Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $2.50 par value KEQUThe Nasdaq Global Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On September 11, 2024, Kewaunee Scientific Corporation issued a press release announcing its financial results for the first quarter of fiscal year 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1Press Release of Kewaunee Scientific Corporation dated September 11, 2024.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: September 11, 2024 By/s/ Donald T. Gardner III Donald T. Gardner III Vice President, Finance Chief Financial Officer
Jun 26, 2024
kequ-20240626KEWAUNEE SCIENTIFIC CORP /DE/FALSE000005552900000555292024-06-262024-06-26
Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024
Kewaunee Scientific Corporation (Exact name of registrant as specified in its charter)
Delaware 0-5286 38-0715562 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)
2700 West Front Street Statesville, NC 28677 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (704) 873-7202 N/A (Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $2.50 par value KEQUThe Nasdaq Global Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On June 26, 2024, Kewaunee Scientific Corporation issued a press release announcing financial results for its fourth quarter and its fiscal year ended April 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1Press Release of Kewaunee Scientific Corporation dated June 26, 2024.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: June 26, 2024 By/s/ Donald T. Gardner III Donald T. Gardner III Vice President, Finance Chief Financial Officer
Mar 6, 2024
kequ-20240306KEWAUNEE SCIENTIFIC CORP /DE/FALSE000005552900000555292024-03-062024-03-06
Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024
Kewaunee Scientific Corporation (Exact name of registrant as specified in its charter)
Delaware 0-5286 38-0715562 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)
2700 West Front Street Statesville, NC 28677 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (704) 873-7202 N/A (Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $2.50 par value KEQUThe Nasdaq Global Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On March 6, 2024, Kewaunee Scientific Corporation issued a press release announcing its financial results for the third quarter of fiscal year 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1Press Release of Kewaunee Scientific Corporation dated March 6, 2024.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: March 6, 2024 By/s/ Donald T. Gardner III Donald T. Gardner III Vice President, Finance Chief Financial Officer
Dec 6, 2023
kequ-20231206KEWAUNEE SCIENTIFIC CORP /DE/FALSE000005552900000555292023-12-062023-12-06
Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023
Kewaunee Scientific Corporation (Exact name of registrant as specified in its charter)
Delaware 0-5286 38-0715562 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)
2700 West Front Street Statesville, NC 28677 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (704) 873-7202 N/A (Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $2.50 par value KEQUThe Nasdaq Global Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On December 6, 2023, Kewaunee Scientific Corporation issued a press release announcing its financial results for the second quarter of fiscal year 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1Press Release of Kewaunee Scientific Corporation dated December 6, 2023.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: December 6, 2023 By/s/ Donald T. Gardner III Donald T. Gardner III Vice President, Finance Chief Financial Officer
Sep 1, 2023
kequ-20230831KEWAUNEE SCIENTIFIC CORP /DE/FALSE000005552900000555292023-08-312023-08-31
Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2023
Kewaunee Scientific Corporation (Exact name of registrant as specified in its charter)
Delaware 0-5286 38-0715562 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)
2700 West Front Street Statesville, NC 28677 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (704) 873-7202 N/A (Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $2.50 par value KEQUThe Nasdaq Global Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On August 31, 2023, Kewaunee Scientific Corporation issued a press release announcing its financial results for the first quarter of fiscal year 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1Press Release of Kewaunee Scientific Corporation dated August 31, 2023.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: August 31, 2023 By/s/ Donald T. Gardner III Donald T. Gardner III Vice President, Finance Chief Financial Officer
Jun 28, 2023
kequ-20230628KEWAUNEE SCIENTIFIC CORP /DE/FALSE000005552900000555292023-06-282023-06-28
Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023
Kewaunee Scientific Corporation (Exact name of registrant as specified in its charter)
Delaware 0-5286 38-0715562 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)
2700 West Front Street Statesville, NC 28677 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (704) 873-7202 N/A (Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $2.50 par value KEQUThe Nasdaq Global Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On June 28, 2023, Kewaunee Scientific Corporation issued a press release announcing its financial results for the fourth quarter and fiscal year ended April 30, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1Press Release of Kewaunee Scientific Corporation dated June 28, 2023.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: June 28, 2023 By/s/ Donald T. Gardner III Donald T. Gardner III Vice President, Finance Chief Financial Officer
Mar 8, 2023
kequ-20230308KEWAUNEE SCIENTIFIC CORP /DE/FALSE000005552900000555292023-03-082023-03-08
Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023
Kewaunee Scientific Corporation (Exact name of registrant as specified in its charter)
Delaware 0-5286 38-0715562 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)
2700 West Front Street Statesville, NC 28677 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (704) 873-7202 N/A (Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $2.50 par value KEQUThe Nasdaq Global Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On March 8, 2023, Kewaunee Scientific Corporation issued a press release announcing its financial results for the third quarter of fiscal year 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1Press Release of Kewaunee Scientific Corporation dated March 8, 2023.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: March 8, 2023 By/s/ Donald T. Gardner III Donald T. Gardner III Vice President, Finance Chief Financial Officer
Dec 8, 2022
kequ-20221207KEWAUNEE SCIENTIFIC CORP /DE/FALSE000005552900000555292022-12-072022-12-07
Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2022
Kewaunee Scientific Corporation (Exact name of registrant as specified in its charter)
Delaware 0-5286 38-0715562 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)
2700 West Front Street Statesville, NC 28677 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (704) 873-7202 N/A (Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $2.50 par value KEQUThe Nasdaq Global Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On December 7, 2022, Kewaunee Scientific Corporation issued a press release announcing its financial results for the second quarter of fiscal year 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1Press Release of Kewaunee Scientific Corporation dated December 7, 2022.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: December 7, 2022 By/s/ Donald T. Gardner III Donald T. Gardner III Vice President, Finance Chief Financial Officer
Sep 8, 2022
kequ-20220908KEWAUNEE SCIENTIFIC CORP /DE/FALSE000005552900000555292022-09-082022-09-08
Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2022
Kewaunee Scientific Corporation (Exact name of registrant as specified in its charter)
Delaware 0-5286 38-0715562 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)
2700 West Front Street Statesville, NC 28677 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (704) 873-7202 N/A (Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $2.50 par value KEQUThe Nasdaq Global Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On September 8, 2022, Kewaunee Scientific Corporation issued a press release announcing its financial results for the first quarter of fiscal year 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1Press Release of Kewaunee Scientific Corporation dated September 8, 2022.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: September 8, 2022 By/s/ Donald T. Gardner III Donald T. Gardner III Vice President, Finance Chief Financial Officer
Jun 30, 2022
kequ-20220629KEWAUNEE SCIENTIFIC CORP /DE/FALSE000005552900000555292022-06-292022-06-29
Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2022
Kewaunee Scientific Corporation (Exact name of registrant as specified in its charter)
Delaware 0-5286 38-0715562 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)
2700 West Front Street Statesville, NC 28677 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (704) 873-7202 N/A (Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $2.50 par value KEQUThe Nasdaq Global Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On June 29, 2022, Kewaunee Scientific Corporation issued a press release announcing its financial results for the fourth quarter and fiscal year ended April 30, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1Press Release of Kewaunee Scientific Corporation dated June 29, 2022.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: June 29, 2022 By/s/ Donald T. Gardner III Donald T. Gardner III Vice President, Finance Chief Financial Officer
Mar 10, 2022
kequ-20220309KEWAUNEE SCIENTIFIC CORP /DE/FALSE000005552900000555292022-03-092022-03-09
Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2022
Kewaunee Scientific Corporation (Exact name of registrant as specified in its charter)
Delaware 0-5286 38-0715562 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.)
2700 West Front Street Statesville, NC 28677 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (704) 873-7202 N/A (Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $2.50 par value KEQUThe Nasdaq Global Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On March 9, 2022, Kewaunee Scientific Corporation issued a press release announcing its financial results for the third quarter of fiscal year 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1Press Release of Kewaunee Scientific Corporation dated March 9, 2022.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: March 9, 2022 By/s/ Donald T. Gardner III Donald T. Gardner III Vice President, Finance Chief Financial Officer
Dec 17, 2021
8-K
KEWAUNEE SCIENTIFIC CORP /DE/ false 0000055529 0000055529 2021-12-16 2021-12-16
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2021
Kewaunee Scientific Corporation (Exact name of registrant as specified in its charter)
Delaware
0-5286
38-0715562
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
2700 West Front Street Statesville, North Carolina
28677
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: 704-873-7202 N/A
(Former name or former address, if changed since last report.) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $2.50 par value
NASDAQ Global Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On December 16, 2021, Kewaunee Scientific Corporation issued a press release announcing its financial results for the second quarter of fiscal year 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits:
Exhibit No.
Description
99.1
Press Release of Kewaunee Scientific Corporation dated December 16, 2021.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
(Registrant)
Kewaunee Scientific Corporation
Date: December 16, 2021
/s/ Donald T. Gardner III
Donald T. Gardner III Vice President, Finance
Chief Financial Officer
Sep 9, 2021
8-K
KEWAUNEE SCIENTIFIC CORP /DE/ false 0000055529 0000055529 2021-09-08 2021-09-08
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2021
Kewaunee Scientific Corporation (Exact name of registrant as specified in its charter)
Delaware
0-5286
38-0715562
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
2700 West Front Street Statesville, North Carolina
28677
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: 704-873-7202 N/A
(Former name or former address, if changed since last report.)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $2.50 par value
NASDAQ Global Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On September 8, 2021, Kewaunee Scientific Corporation issued a press release announcing its financial results for the first quarter of fiscal year 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits:
Exhibit No.
Description
99.1
Press Release of Kewaunee Scientific Corporation dated September 8, 2021.
104
Cover Page Interactive Data File (embedded within Inline XBRL document)
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
(Registrant)
Kewaunee Scientific Corporation
Date: September 8, 2021
/s/ Donald T. Gardner III
Donald T. Gardner III
Vice President, Finance and Chief Financial Officer
Jul 9, 2021
8-K 1 d196981d8k.htm 8-K
8-K
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 8, 2021
Kewaunee Scientific Corporation
(Exact name of registrant as specified in its charter)
Delaware
0-5286
38-0715562
(State or other jurisdictionof incorporation)
(CommissionFile Number)
(I.R.S. EmployerIdentification No.)
2700 West Front Street
Statesville, North Carolina
28677
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: 704-873-7202 N/A
(Former name or former address, if changed since last report.) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange
on which registered
Common Stock, $2.50 par value
NASDAQ Global Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On July 8, 2021, Kewaunee Scientific Corporation issued a press release announcing its financial results for the fourth quarter and fiscal year ended April 30, 2021. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits:
Exhibit No.
99.1
Press Release of Kewaunee Scientific Corporation dated July 8, 2021.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
(Registrant)
Kewaunee Scientific Corporation
Date: July 8, 2021
/s/ Donald T. Gardner III
Donald T. Gardner III Vice President, Finance and
Chief Financial Officer
This page provides Kewaunee Scientific Corporation (KEQU) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on KEQU's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.